XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period $ 2,430,637,724 $ 2,400,299,527 $ 2,472,099,655 [1] $ 2,312,517,069
Issuance of common stock from stock plan transactions (in shares)     1,600,000  
Issuance of common stock from stock plan transactions 7,054,311 3,782,044 $ 13,338,052 24,024,353
Repurchases of common stock (in shares)     (9,800,000)  
Repurchases of common stock (28,283,469) (96,339,949) $ (230,450,683) (187,678,611)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 10,436,395 9,540,105 26,596,685 30,936,895
Dividends declared (26,274,216) (27,293,155) (79,595,804) (82,663,756)
Capital contributions, net     442,500  
Fair value of non-controlling interest in EyeLock LLC     656,000  
Net income (loss) 100,968,655 [2] 122,549,041 291,825,889 [3] 316,820,194
Other comprehensive income 750,426 5,089,729 3,763,118 3,671,198
Balance at end of period 2,495,214,826 2,417,627,342 2,495,214,826 2,417,627,342
EyeLock LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments (75,000)   (75,000)  
BioCenturion LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments     (3,385,586)  
Parent        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 2,430,038,168 2,400,299,527 2,467,950,655 2,312,517,069
Issuance of common stock from stock plan transactions 7,054,311 3,782,044 13,338,052 24,024,353
Repurchases of common stock (28,283,469) (96,339,949) (230,450,683) (187,678,611)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 10,436,395 9,540,105 26,596,685 30,936,895
Dividends declared (26,274,216) (27,293,155) (79,595,804) (82,663,756)
Net income (loss) 100,967,910 [2] 122,549,041 291,881,539 [3] 316,820,194
Other comprehensive income 750,426 5,089,729 3,763,118 3,671,198
Balance at end of period 2,495,214,826 $ 2,417,627,342 2,495,214,826 $ 2,417,627,342
Parent | EyeLock LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments $ 525,301   525,301  
Parent | BioCenturion LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments     $ 1,205,963  
Common Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period (in shares) 219,520,750 230,229,539 227,207,472 231,455,443
Balance at beginning of period $ 13,171,245 $ 13,813,772 $ 13,632,448 $ 13,887,326
Issuance of common stock from stock plan transactions (in shares) 434,634 408,566 1,550,327 1,786,232
Issuance of common stock from stock plan transactions $ 26,078 $ 24,514 $ 93,020 $ 107,174
Repurchases of common stock (in shares) (1,003,580) (3,194,815) (9,805,995) (5,798,385)
Repurchases of common stock $ (60,215) $ (191,689) $ (588,360) $ (347,903)
Balance at end of period (in shares) 218,951,804 227,443,290 218,951,804 227,443,290
Balance at end of period $ 13,137,108 $ 13,646,597 $ 13,137,108 $ 13,646,597
Additional  Paid-In Capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 998,911,809 1,000,014,813 1,010,440,420 968,245,875
Issuance of common stock from stock plan transactions 7,028,233 3,757,530 13,245,032 23,917,179
Repurchases of common stock (4,044,427) (12,363,936) (39,156,090) (22,151,437)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 10,436,395 9,540,105 26,596,685 30,936,895
Balance at end of period 1,012,857,311 1,000,948,512 1,012,857,311 1,000,948,512
Additional  Paid-In Capital | EyeLock LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments 525,301   525,301  
Additional  Paid-In Capital | BioCenturion LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments     1,205,963  
Retained  Earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 1,421,351,763 1,394,446,595 1,450,287,128 1,336,940,990
Repurchases of common stock (24,178,827) (83,784,324) (190,706,233) (165,179,271)
Dividends declared (26,274,216) (27,293,155) (79,595,804) (82,663,756)
Net income (loss) 100,967,910 [2] 122,549,041 291,881,539 [3] 316,820,194
Balance at end of period 1,471,866,630 1,405,918,157 1,471,866,630 1,405,918,157
Accumulated  Other Comprehensive Income (Loss)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period (3,396,649) (7,975,653) (6,409,341) (6,557,122)
Other comprehensive income 750,426 5,089,729 3,763,118 3,671,198
Balance at end of period (2,646,223) (2,885,924) (2,646,223) (2,885,924)
Equity Attributable to Noncontrolling Interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 599,556 0 4,149,000 0
Capital contributions, net     442,500  
Fair value of non-controlling interest in EyeLock LLC     656,000  
Net income (loss) 745 [2]   (55,650) [3]  
Balance at end of period 0 $ 0 0 $ 0
Equity Attributable to Noncontrolling Interests | EyeLock LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments $ (600,301)   (600,301)  
Equity Attributable to Noncontrolling Interests | BioCenturion LLC        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Purchase of additional interest in investments     $ (4,591,549)  
[1] The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date, but does not include all of the inflation and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
[2] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $81,902 for the three months ended September 30, 2025 (see Note 16).
[3] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $414,641 for the nine months ended September 30, 2025 (see Note 16).